{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:43:15Z","timestamp":1776091395866,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,13]]},"DOI":"10.7759\/cureus.62338","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T02:09:57Z","timestamp":1718330997000},"source":"Crossref","is-referenced-by-count":1,"title":["Pathologic Complete Response to Neoadjuvant Chemotherapy and Pembrolizumab in Postpartum High-Risk Basal-Type Breast Cancer"],"prefix":"10.7759","author":[{"given":"Heng","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Cartwright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jairam","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan A","family":"Santamaria-Barria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau C","year":"2022","unstructured":"Yau C, Osdoit M, van der Noordaa M, et al.. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022, 23:149-60. 10.1016\/S1470-2045(21)00589-1","journal-title":"Lancet Oncol"},{"key":"ref2","unstructured":"National Comprehensive Cancer Network. Breast cancer, version 4. (2023). Accessed: September 9, 2023: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid P","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, et al.. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022, 386:556-67. 10.1056\/NEJMoa2112651","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3908-y","article-title":"Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)","volume":"21","author":"Whitworth P","year":"2014","unstructured":"Whitworth P, Stork-Sloots L, de Snoo FA, et al.. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST). Ann Surg Oncol. 2014, 21:3261-7. 10.1245\/s10434-014-3908-y","journal-title":"Ann Surg Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.521","article-title":"MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST","volume":"41","author":"Beitsch PD","year":"2023","unstructured":"Beitsch PD, Pellicane JV, Pusztai L, et al.. MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST. J Clin Oncol. 2023, 41:521. 10.1200\/JCO.2023.41.16_suppl.521","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.011","article-title":"Lba21 KEYNOTE 756: phase III study of neoadjuvant pembrolizumab (Pembro) or placebo (PBO)+ chemotherapy (Chemo), followed by adjuvant Pembro or PBO+ endocrine therapy (ET) for early-stage high-risk ER+\/Her2-breast cancer","volume":"34","author":"Cardoso F","year":"2023","unstructured":"Cardoso F, McArthur H, Schmid P, et al.. Lba21 KEYNOTE 756: phase III study of neoadjuvant pembrolizumab (Pembro) or placebo (PBO)+ chemotherapy (Chemo), followed by adjuvant Pembro or PBO+ endocrine therapy (ET) for early-stage high-risk ER+\/Her2-breast cancer. Ann Oncol. 2023, 34:1260-1. 10.1016\/j.annonc.2023.10.011","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien V","year":"2023","unstructured":"Debien V, De Caluw\u00e9 A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, Buisseret L. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023, 9:7. 10.1038\/s41523-023-00508-3","journal-title":"NPJ Breast Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring LM","year":"2020","unstructured":"Spring LM, Fell G, Arfe A, et al.. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020, 26:2838-48. 10.1158\/1078-0432.CCR-19-3492","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00007-3","article-title":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","volume":"22","author":"Piccart M","year":"2021","unstructured":"Piccart M, van 't Veer LJ, Poncet C, et al.. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021, 22:476-88. 10.1016\/S1470-2045(21)00007-3","journal-title":"Lancet Oncol"},{"key":"ref10","unstructured":"BluePrint. molecular subtyping test. (2023). Accessed: January 18, 2024: https:\/\/agendia.com\/blueprint\/."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-6534-z","article-title":"MammaPrint guides treatment decisions in breast cancer: results of the IMPACt trial","volume":"20","author":"Soliman H","year":"2020","unstructured":"Soliman H, Shah V, Srkalovic G, et al.. MammaPrint guides treatment decisions in breast cancer: results of the IMPACt trial. BMC Cancer. 2020, 20:81. 10.1186\/s12885-020-6534-z","journal-title":"BMC Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: prognostic and therapeutic implications","volume":"5","author":"Yersal O","year":"2014","unstructured":"Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol. 2014, 5:412-24. 10.5306\/wjco.v5.i3.412","journal-title":"World J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.563","article-title":"Molecular profiles of genomically high risk ER+ HER2- breast cancer tumors classified as functionally basal or luminal B by the 80-gene signature","volume":"39","author":"O'Shaughnessy J","year":"2021","unstructured":"O'Shaughnessy J, Kaklamani VG, Yuan Y, et al.. Molecular profiles of genomically high risk ER+ HER2- breast cancer tumors classified as functionally basal or luminal B by the 80-gene signature. J Clin Oncol. 2021, 39:563. 10.1200\/JCO.2021.39.15_suppl.563","journal-title":"J Clin Oncol"},{"key":"ref14","unstructured":"Developing studies. S2206 phase III trial of neoadjuvant durvalumab (NSC 778709) plus chemotherapy versus chemotherapy alone for MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive\/human epidermal growth factor receptor (HER2) negative stage II. (2023). Accessed: February 10, 2024: https:\/\/www.swog.org\/sites\/default\/files\/docs\/2023-04\/Breast_Spr23.pdf."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.3755","article-title":"Surrogacy of pathologic complete response in trials of neoadjuvant therapy for early breast cancer: critical analysis of strengths, weaknesses, and misinterpretations","volume":"8","author":"Conforti F","year":"2022","unstructured":"Conforti F, Pala L, Bagnardi V, et al.. Surrogacy of pathologic complete response in trials of neoadjuvant therapy for early breast cancer: critical analysis of strengths, weaknesses, and misinterpretations. JAMA Oncol. 2022, 8:1668-75. 10.1001\/jamaoncol.2022.3755","journal-title":"JAMA Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2023.103580","article-title":"Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive\/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8","volume":"72","author":"Jerusalem G","year":"2023","unstructured":"Jerusalem G, Prat A, Salgado R, et al.. Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive\/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8. Breast. 2023, 72:103580. 10.1016\/j.breast.2023.103580","journal-title":"Breast"},{"key":"ref17","unstructured":"I-SPY TRIAL. neoadjuvant and personalized adaptive novel agents to treat breast cancer (I-SPY). (2024). Accessed: January 18, 2024: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01042379."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2260","article-title":"Neoadjuvant chemotherapy and immunotherapy in luminal B-like breast cancer: results of the Phase II GIADA trial","volume":"28","author":"Dieci MV","year":"2022","unstructured":"Dieci MV, Guarneri V, Tosi A, et al.. Neoadjuvant chemotherapy and immunotherapy in luminal B-like breast cancer: results of the Phase II GIADA trial. Clin Cancer Res. 2022, 28:308-17. 10.1158\/1078-0432.CCR-21-2260","journal-title":"Clin Cancer Res"},{"key":"ref19","unstructured":"Neoadjuvant pembrolizumab + decitabine followed by STD Neoadj chemo for locally advanced HER2- breast cancer. (2024). Accessed. January 18, 2024: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02957968."},{"key":"ref20","unstructured":"Neo-adjuvant chemotherapy combined with stereotactic body radiotherapy to the primary tumour +\/- durvalumab, +\/- oleclumab in luminal B breast cancer. (neo-Checkray). (2024). Accessed: January 18, 2024: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03875573."},{"key":"ref21","unstructured":"Pre-op Pembro + radiation therapy in breast cancer (P-RAD). (2024). Accessed. January 18, 2024: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04443348."},{"key":"ref22","unstructured":"Study of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant chemotherapy & adjuvant endocrine therapy in the treatment of early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+\/HER2-) breast cancer (MK-3475-756\/KEYNOTE-756). (2024). Accessed. January 18, 2024: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03725059."},{"key":"ref23","unstructured":"Durvalumab and tremelimumab before surgery in treating patients with hormone receptor positive, HER2 negative stage II-III breast cancer. (2024). Accessed. January 18, 2024: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03132467."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s10911-009-9119-7","article-title":"Pregnancy and breast cancer: when they collide","volume":"14","author":"Lyons TR","year":"2009","unstructured":"Lyons TR, Schedin PJ, Borges VF. Pregnancy and breast cancer: when they collide. J Mammary Gland Biol Neoplasia. 2009, 14:87-98. 10.1007\/s10911-009-9119-7","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00183-2","article-title":"The definition of pregnancy-associated breast cancer is outdated and should no longer be used","volume":"22","author":"Amant F","year":"2021","unstructured":"Amant F, Lefr\u00e8re H, Borges VF, et al.. The definition of pregnancy-associated breast cancer is outdated and should no longer be used. Lancet Oncol. 2021, 22:753-4. 10.1016\/S1470-2045(21)00183-2","journal-title":"Lancet Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6335","article-title":"Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study","volume":"31","author":"Amant F","year":"2013","unstructured":"Amant F, von Minckwitz G, Han SN, et al.. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013, 31:2532-9. 10.1200\/JCO.2012.45.6335","journal-title":"J Clin Oncol"},{"key":"ref27","article-title":"Pembrolizumab","author":"National Institute of Child Health and Human Development","year":"2006","unstructured":"National Institute of Child Health and Human Development. Pembrolizumab. Drugs and Lactation Database (LactMed\u00ae). National Institute of Child Health and Human Development, Bethesda; 2006."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/256711-pathologic-complete-response-to-neoadjuvant-chemotherapy-and-pembrolizumab-in-postpartum-high-risk-basal-type-breast-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T02:10:08Z","timestamp":1718331008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/256711-pathologic-complete-response-to-neoadjuvant-chemotherapy-and-pembrolizumab-in-postpartum-high-risk-basal-type-breast-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.62338","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,13]]}}}